MedTrace Logo

Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)

NCT00989612 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-01-16

Study results available
· View outcomes & findings →

Summary

This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.

Conditions

Interventions

BIOLOGICAL

Influenza investigational vaccine GSK2340274A

Two intramuscular injections on Day 0 and Day 21, respectively

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-01
Primary Completion
2010-04-19
Completion
2010-04-19

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989612 on ClinicalTrials.gov